Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.
Neurenati Therapeutics has raised $1.7M in total funding. The most recent round was Seed. The last funding was announced in April 2024.
Neurenati Therapeutics's investors include Investissement Quebec, Genson Capital.
Neurenati Therapeutics is headquartered in Montreal, Canada.
Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.
Neurenati Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurenati Therapeutics — Funding & Investors." VCBacked, April 18, 2024, https://www.vcbacked.co/company/neurenati-therapeutics. Accessed September 14, 2026.
VCBacked. (2024). Neurenati Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/neurenati-therapeutics
{{cite web |title=Neurenati Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neurenati-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated